358 related articles for article (PubMed ID: 38799237)
21. The role of novel adipokines and adipose-derived extracellular vesicles (ADEVs): Connections and interactions in liver diseases.
Xie L; Wang H; Hu J; Liu Z; Hu F
Biochem Pharmacol; 2024 Apr; 222():116104. PubMed ID: 38428826
[TBL] [Abstract][Full Text] [Related]
22. Myostatin and adipokines: The role of the metabolically unhealthy obese phenotype in muscle function and aerobic capacity in young adults.
Carvalho LP; Basso-Vanelli RP; Di Thommazo-Luporini L; Mendes RG; Oliveira-Junior MC; Vieira RP; Bonjorno-Junior JC; Oliveira CR; Luporini R; Borghi-Silva A
Cytokine; 2018 Jul; 107():118-124. PubMed ID: 29246653
[TBL] [Abstract][Full Text] [Related]
23. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.
Jung UJ; Choi MS
Int J Mol Sci; 2014 Apr; 15(4):6184-223. PubMed ID: 24733068
[TBL] [Abstract][Full Text] [Related]
24. Organokines in disease.
Chung HS; Choi KM
Adv Clin Chem; 2020; 94():261-321. PubMed ID: 31952573
[TBL] [Abstract][Full Text] [Related]
25. The role of adiponectin for immune cell function in metabolic diseases.
Gao M; Cui D; Xie J
Diabetes Obes Metab; 2023 Sep; 25(9):2427-2438. PubMed ID: 37272314
[TBL] [Abstract][Full Text] [Related]
26. [Adiponectin and parameters of glucose and lipid metabolism at different clinical and morphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity].
Komshilova KA; Troshina EA; Ershova EV; Mazurina NV; Platonova NM
Ter Arkh; 2014; 86(10):27-32. PubMed ID: 25509888
[TBL] [Abstract][Full Text] [Related]
27. Porcine adiponectin receptor 1 transgene resists high-fat/sucrose diet-induced weight gain, hepatosteatosis and insulin resistance in mice.
Liu BH; Lin YY; Wang YC; Huang CW; Chen CC; Wu SC; Mersmann HJ; Cheng WT; Ding ST
Exp Anim; 2013; 62(4):347-60. PubMed ID: 24172199
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
29. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders.
Chen Z; Wang GX; Ma SL; Jung DY; Ha H; Altamimi T; Zhao XY; Guo L; Zhang P; Hu CR; Cheng JX; Lopaschuk GD; Kim JK; Lin JD
Mol Metab; 2017 Aug; 6(8):863-872. PubMed ID: 28752050
[TBL] [Abstract][Full Text] [Related]
30. Adipose tissue homeostasis orchestrates the oxidative, energetic, metabolic and endocrine disruption induced by binge drinking in adolescent rats.
Romero-Herrera I; Nogales F; Gallego-López MDC; Díaz-Castro J; Moreno-Fernandez J; Ochoa JJ; Carreras O; Ojeda ML
J Physiol; 2023 Dec; 601(24):5617-5633. PubMed ID: 37994192
[TBL] [Abstract][Full Text] [Related]
31. Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease.
Ishtiaq SM; Rashid H; Hussain Z; Arshad MI; Khan JA
Rev Endocr Metab Disord; 2019 Sep; 20(3):253-261. PubMed ID: 31656991
[TBL] [Abstract][Full Text] [Related]
32. Adiponectin--a key adipokine in the metabolic syndrome.
Whitehead JP; Richards AA; Hickman IJ; Macdonald GA; Prins JB
Diabetes Obes Metab; 2006 May; 8(3):264-80. PubMed ID: 16634986
[TBL] [Abstract][Full Text] [Related]
33. Sarcopenic obesity in fatty liver.
Merli M; Lattanzi B; Aprile F
Curr Opin Clin Nutr Metab Care; 2019 May; 22(3):185-190. PubMed ID: 30893090
[TBL] [Abstract][Full Text] [Related]
34. [Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker].
Chellali S; Boudiba A; Griene L; Koceir EA
Ann Biol Clin (Paris); 2019 Jun; 77(3):261-271. PubMed ID: 30998190
[TBL] [Abstract][Full Text] [Related]
35. Adiponectin: A multitasking player in the field of liver diseases.
Silva TE; Colombo G; Schiavon LL
Diabetes Metab; 2014 Apr; 40(2):95-107. PubMed ID: 24486145
[TBL] [Abstract][Full Text] [Related]
36. LMO3 reprograms visceral adipocyte metabolism during obesity.
Wagner G; Fenzl A; Lindroos-Christensen J; Einwallner E; Husa J; Witzeneder N; Rauscher S; Gröger M; Derdak S; Mohr T; Sutterlüty H; Klinglmüller F; Wolkerstorfer S; Fondi M; Hoermann G; Cao L; Wagner O; Kiefer FW; Esterbauer H; Bilban M
J Mol Med (Berl); 2021 Aug; 99(8):1151-1171. PubMed ID: 34018016
[TBL] [Abstract][Full Text] [Related]
37. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
Francisco V; Sanz MJ; Real JT; Marques P; Capuozzo M; Ait Eldjoudi D; Gualillo O
Biology (Basel); 2022 Aug; 11(8):. PubMed ID: 36009862
[TBL] [Abstract][Full Text] [Related]
38. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance.
Zheng H; Li S; Ma L; Cheng L; Deng C; Chen Z; Xie C; Xiang M; Jiang W; Chen L
Eur J Pharmacol; 2011 Jun; 659(2-3):244-51. PubMed ID: 21463618
[TBL] [Abstract][Full Text] [Related]
39. Low level of adiponectin predicts the development of Nonalcoholic fatty liver disease: is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices?
Ebrahimi R; Shanaki M; Mohassel Azadi S; Bahiraee A; Radmard AR; Poustchi H; Emamgholipour S
Arch Physiol Biochem; 2022 Feb; 128(1):24-31. PubMed ID: 31482741
[TBL] [Abstract][Full Text] [Related]
40. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents.
Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR
Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
